Canaccord lowered the firm’s price target on Pulmonx (LUNG) to $15 from $16 and keeps a Buy rating on the shares. The firm said they reported a relatively in-line first quarter and the company reiterated the 2025 guidance that it already provided. The company is confident that its OUS business in the near term will also not be impacted, expecting continued orders from China.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on LUNG:
Looking for a trading platform? Check out TipRanks' Best Online Brokers , and find the ideal broker for your trades.
Report an Issue